Everything your team needs to start testing, get results, and build NavDx testing seamlessly into your practice workflow.
Every NavDx result report includes three components:
Before reviewing results with patients, it helps to frame what the NavDx test is, and what it isn’t. NavDx testing detects TTMV-HPV DNA: fragments of DNA released by active HPV+ cancer cells. It does not detect HPV infection itself, so patients with prior HPV exposure will not test positive unless active cancer cells are shedding DNA into their bloodstream. It is a monitoring tool; not a diagnostic test for initial cancer diagnosis.
TTMV-HPV DNA was detected in the blood at the time of the draw. A positive result does not confirm active cancer. It is a signal that warrants further clinical investigation.
Suggested patient language:
TTMV-HPV DNA was not detected at the time of the draw. With a NPV of ≥98%, a negative result is highly reassuring. It means active HPV+ cancer cells were very unlikely to be present at the time of the blood draw.
Suggested patient language:
Important framing: A negative result does not mean cancer can never return. Continued regular surveillance remains essential. This result is a reassuring data point, not a discharge.
The test could not produce a clear positive or negative result for this draw. Indeterminate results occur in approximately 3% of OPSCC tests and 1.3–1.9% of ASCC tests, significantly less frequently than conventional surveillance methods, which produce clinically indeterminate findings in up to 40% of visits.
Suggested patient language:
The California Head and Neck Consortium (CHNC) notes that “positive ctHPVDNA without clinical/radiographic evidence often increases patient distress” (81.8% strong consensus).11 Proactive communication before and after testing, including clear framing of what a positive result does and does not mean, is an important part of integrating NavDx testing into clinical practice.
Consider briefing patients at their first post-treatment visit on what the NavDx test is, how often they’ll be tested, and what the three possible results mean before any results are available. A patient-facing brochure and discussion guide are available in the Provider Resources section.
The NavDx Surveillance Testing Program is designed to reduce administrative burden on your practice while keeping patients consistently on track with their long-term monitoring schedule.
One annual order covers 12 months.
Place a single NavDx test order per patient and set the testing cadence (every 3, 4, or 6 months) based on clinical need.
You stay in control.
Testing frequency can be adjusted at any time. Clinical decisions remain entirely with the Provider.
No baseline required.
You can enroll a patient in the surveillance program at any time. A pre-treatment baseline test is not required to use NavDx testing for post-treatment monitoring.
We can help keep patients on schedule.
As each testing window approaches, our in-house Patient Navigation Team will proactively contact patients to schedule their blood draw, reducing missed tests without additional work from your staff.
Results before visits.
With NavDx-Arranged Phlebotomy, blood draws are scheduled before follow-up appointments, so results are in-hand when the patient arrives.
Visit the Order NavDx page to place your first order, or contact our Clinical Operations Team at (833) 628-3747 or clinops@naveris.com for help setting up your practice.
